Literature DB >> 23714509

Treatment and trials: ovarian cancer in older women.

G Freyer1, W P Tew, K N Moore.   

Abstract

Ovarian cancer (OC) is a disease of elderly women. The disease spreads insidiously and presents at an advanced stage at initial diagnosis for most patients. Several groups reported at least a two-fold increased risk of death in women older than 65. Various theories have been proposed to explain this survival disparity in older women, including: (1) more aggressive cancer with advanced age, (2) inherent resistance to chemotherapy, (3) individual patient factors such as multiple concurrent medical problems, and (4) physician and health-care biases toward the elderly that lead to inadequate surgery, less than optimal chemotherapy, and poor enrollment in clinical trials. As a result of this high clinical variability, oncologists need to be more familiar with the comprehensive geriatric assessment to better identify vulnerable patients at higher risk of complications. Several geriatric tools are available to assess the physiologic and functional capacities of older patients and to better individualize treatment. This paper gives an overview of the management of elderly patients with OC, in particular the integration of chemotherapy, surgery, and geriatric assessment to improve treatment tolerance and survival outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23714509     DOI: 10.14694/EdBook_AM.2013.33.227

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  2 in total

1.  Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.

Authors:  S B Dessai; S Chakraborty; T V S Babu; S Nayanar; A Bhattacharjee; J Jones; S Balasubramanian; Vijay M Patil
Journal:  South Asian J Cancer       Date:  2016 Apr-Jun

Review 2.  The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years.

Authors:  Steven J Gibson; Gini F Fleming; Sarah M Temkin; Dana M Chase
Journal:  Front Oncol       Date:  2016-03-24       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.